Core Insights - Ernexa Therapeutics has shifted its strategic focus from a cell therapy platform to prioritizing product development, emphasizing its commitment to patient impact with the new tagline "Breaking Through Defenses, Delivering Hope" [1][2] Company Overview - Ernexa Therapeutics, formerly Eterna Therapeutics, is a leader in cell therapies targeting advanced cancer and autoimmune diseases, with a focus on engineering induced pluripotent stem cells (iPSCs) into induced mesenchymal stem cells (iMSCs) [1][6] - The company aims to provide scalable, off-the-shelf treatment solutions through its allogeneic synthetic iMSCs, addressing challenges such as immune rejection and donor shortages [2][6] Product Development - Ernexa is developing two cell therapy products currently in preclinical trials: ERNA-101, aimed at enhancing the immune system's response to cancer, and ERNA-102, designed to treat inflammation and autoimmune diseases [3][7] - ERNA-101 is specifically being developed for ovarian cancer, a field with significant unmet medical needs due to the lack of effective targeted therapies [4][5] Market Potential - The company highlights the potential of ERNA-101 and ERNA-102 to significantly impact the treatment landscape for ovarian cancer and autoimmune diseases, respectively [5][7]

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Fiscal Year Ended December 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ________ to ________ Commission File Number 1-11460 Eterna Therapeutics Inc. (Exact name of registrant as specified in its charter) Delaware 31-1103425 (State or O ...

Core Insights - Eterna Therapeutics is advancing its induced mesenchymal stem cell (iMSC) therapy programs for treating advanced solid tumors and autoimmune diseases, with a successful inaugural meeting of its Scientific Advisory Board focusing on preclinical advances and clinical trial roadmaps [1][2][3] Company Overview - Eterna Therapeutics (Nasdaq: ERNA) specializes in innovative cell therapies, particularly through engineering induced pluripotent stem cells (iPSCs) into iMSCs, offering scalable, off-the-shelf treatment solutions without the need for patient-specific cell harvesting [4] Product Development - The company is developing two lead products: ERNA-101, aimed at activating the immune system to target cancer cells, and ERNA-102, designed to address inflammation in autoimmune diseases, with a primary focus on ovarian cancer for ERNA-101 [5][8] Scientific Advisory Board Insights - The Scientific Advisory Board includes leading experts who engaged in discussions about advancing next-generation cell therapies, emphasizing the importance of scientific rigor and innovation [2][7] - Highlights from the meeting included positive preclinical data for ERNA-101, strategies for optimizing dosage and administration routes, and potential combination therapies with CAR-T therapy and other immunomodulatory approaches [8] Future Directions - Eterna plans to continue collaboration with the Scientific Advisory Board and stakeholders to translate innovative therapies into clinical practice, with a focus on rigorous quality, safety, and efficacy criteria [3][8]

CAMBRIDGE, Mass., Jan. 28, 2025 (GLOBE NEWSWIRE) -- Eterna Therapeutics (NASDAQ:ERNA), a leader in cell therapies for the treatment of advanced solid tumors, today announced the addition of Jerome Zeldis, M.D., Ph.D., and Blythe Sather, Ph.D., to the company's scientific advisory board. "We are fortunate to welcome Dr. Zeldis and Dr. Sather," said Sanjeev Luther, President & CEO of Eterna Therapeutics. "Their extensive experience in developing transformative, high-profile cell therapies for solid tumors has ...

New data from proof-of-concept study provides roadmap for treatment of ovarian cancerCAMBRIDGE, Mass., Jan. 14, 2025 (GLOBE NEWSWIRE) -- Eterna Therapeutics (Nasdaq: ERNA), a leader in cell therapies for the treatment of advanced solid tumors, today announced positive results from a preclinical study on the company’s lead cell therapy product, ERNA-101, which is designed to activate and regulate the immune system's response to recognize and attack ovarian cancer cells. This successful proof-of-concept study ...

Company Announcement - Eterna Therapeutics appoints Dr Elena Ratner to its Board of Directors to lead strategic efforts in ovarian cancer research and treatment [1][2] - Dr Ratner brings extensive expertise in obstetrics gynecology and reproductive sciences from Yale University [1][4] - Eterna aims to accelerate advancements in innovative therapies for ovarian and breast cancers leveraging Dr Ratner's leadership and recent collaboration with MD Anderson Cancer Center [2] Product Development - Eterna's lead product ERNA-101 is an allogeneic pro-inflammatory cytokine (IL-7/IL-15)-secreting iMSC therapy targeting platinum-resistant ovarian cancer [5] - ERNA-101 enhances immune system response against tumors by improving immune cell infiltration and activation [3] - The company is also investigating ERNA-102 anti-inflammatory cytokine (IL-10)-secreting iMSCs for inflammatory/auto-immune disorders like rheumatoid arthritis [5] Strategic Direction - Eterna is actively seeking strategic partnerships to co-develop or out-license therapeutic assets and expand developmental opportunities [5] - The company's focus on women's health is reinforced by its collaboration with MD Anderson Cancer Center and Dr Ratner's expertise [2][4] - Eterna's scientific data shows promise in addressing the challenges of ovarian cancer treatment including resistance and high recurrence rates [3]

CAMBRIDGE, Mass., Nov. 14, 2024 (GLOBE NEWSWIRE) -- Eterna Therapeutics Inc. (Nasdaq: ERNA) (“Eterna” or the “Company”) announced today that it has regained compliance with Nasdaq for continued listing and that its stock will continue to trade on The Nasdaq Stock Market. Eterna received formal confirmation on November 12th, 2024 from Nasdaq’s Office of General Counsel, verifying that Eterna has met the market value of listed securities standard of at least $35 million, outlined in Listing Rule 5550(b)(2), a ...

CAMBRIDGE, Mass., Oct. 30, 2024 (GLOBE NEWSWIRE) -- Eterna Therapeutics Inc. (Nasdaq: ERNA) ("Eterna" or the "Company") today announced the successful completion of a comprehensive financial restructuring of the Company with the aim to accelerate its developmental activities and long-term success. This restructuring includes reduction of its liabilities by discontinuing a longstanding lease, reducing the debt on its balance sheet and a new round of financing through a private investment in public equity (PI ...

CAMBRIDGE, Mass., Oct. 17, 2024 (GLOBE NEWSWIRE) -- Eterna Therapeutics Inc. (Nasdaq: ERNA) ("Eterna" or the "Company") and Factor Bioscience Limited ("Factor") today announced an exclusive license and collaboration agreement aimed at accelerating the development of advanced cell therapy candidates for oncology, rare diseases, and autoimmune disorders. Under the terms of the agreement, Eterna has secured a worldwide, exclusive, non-transferable, royalty-bearing license, with the right to grant sublicenses, ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _________ to _____________ Commission file number: 001-11460 Eterna Therapeutics Inc. (Exact name of registrant as specified in its charter) Delaware 31-11034 ...